Background: Chronic stress worsens the quality of life (QOL) of lupus patients by affecting their physical and psychological status. The effectiveness of a cognitive-behavioural intervention in a group of patients with lupus and high levels of daily stress was investigated. Methods: Forty-five patients with lupus and high levels of daily stress were randomly assigned to a control group (CG) or a therapy group (TG); they received cognitive behavioural therapy (CBT) which consisted of ten consecutive weekly sessions. The following variables were evaluated at baseline and at 3, 9 and 15 months: (1) stress, anxiety, depression, (2) Systemic Lupus Erythematosus Disease Activity Index, somatic symptoms, number of flares, (3) anti-nDNA antibodies, complement fractions C3 and C4 and (4) QOL. A multivariate analysis of repeated measures and various analyses of variance were carried out. Results: We found a significant reduction in the level of depression, anxiety and daily stress in the TG compared to the CG and a significant improvement in QOL and somatic symptoms in the TG throughout the entire follow-up period. We did not find any significant changes in the immunological parameters. Conclusions: CBT is effective in dealing with patients suffering from lupus and high levels of daily stress as it significantly reduces the incidence of psychological disorders associated with lupus and improves and maintains patients’ QOL, despite there being no significant reduction in the disease activity index.

Keywords:
Lupus, Stress, Depression, Cognitive-behavioural therapy, Quality of life
1.
Dostal C, Marek J, Moszkorzova L, Lacinova Z, Musilova L, Zvarova J: Effects of stress on serum prolactin levels in patients with systemic lupus erythematosus. Ann NY Acad Sci 2002;966:247–251.
2.
Kozora E, Ellison MC, Waxmansky JA, Wamboldt FS, Patterson TL: Major life stress, coping styles and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005;14:363–372.
3.
Wekking EM, Vingerhoets AJ: Daily stressors and systemic lupus erythematosus: a longitudinal analysis – first findings. Psychother Psychosom 1991;55:108–113.
4.
Adams SG, Dammers PM, Saia TL, Brantley PJ, Gaydos GR: Stress, depression and anxiety predict average symptom severity and daily symptom fluctuation in systemic lupus erythematosus. J Behav Med 1994;17:459–477.
5.
Schubert C, Lampe A, Rumpold G, Fuchs D, König P, Chamson E, Schatz D, König P, Fuchs D, Schüssler G: Daily psychosocial stressors interfere with the dynamics of urine neopterin in a patient with systemic lupus erythematosus: an integrative single-case study. Psychosom Med 1999;6:876–882.
6.
Schubert C, Lampe A, Geser W, Noisternig B, Fuchs D, Konig P, Chamson E, Schüssler G: Daily psychosocial stressors and cyclic response patterns in urine cortisol and neopterin in a patient with systemic lupus erythematosus. Psychoneuroendocrinology 2003;28:459–473.
7.
Schubert C, Geser W, Noisternig B, Konig P, Rumpold G, Lampe A: Stressful life events and skin diseases: An additional perspective from research on psychosomatic dynamics in systemic lupus erythematosus. Psychother Psychosom 2002;71:123–126.
8.
Peralta-Ramírez MI, Jiménez-Alonso J, Godoy-García JF, Pérez-Garcia M: The effects of daily stress and stressful life events on the clinical symptomatology of patients with lupus erythematosus. Psychosom Med 2004;66:788–794.
9.
Pawlack CR, Witte T, Heiken H, Hundt M, Schubert J, Wiese B, Bischoff-Renken A, Gerber K, Licht B, Goebel MU, Heijnen CJ, Schmidt RE, Schedlowski M:Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. Psychother Psychosom 2003;72:159–165.
10.
Peralta-Ramírez MI, Coín-Mejías MA, Jiménez-Alonso J, Ortego-Centeno N, Callejas-Rubio JL, Caracuel-Romero A, Pérez-García M: Stress as a predictor of cognitive functioning in lupus. Lupus 2006;15:858–864.
11.
Herrmann M, Scholmerich J, Straub RH: Stress and rheumatic diseases. Rheum Dis Clin North Am 2000;26:737–763.
12.
Wilder RL: Neuroimmunoendocrinology of the rheumatic diseases: past, present and future. Ann NY Acad Sci 2002;966:13–19.
13.
Van Hout MS, Wekking EM, Berg IJ, Deelman BG: Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. Psychother Psychosom 2008;77:289–297.
14.
Andersen BL, Yang HC, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LM, Young DC, Carson WE 3rd: Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008;113:3450–3458.
15.
Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH: Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 2009;78:6–15.
16.
Janeway D: An integrated approach to the diagnosis and treatment of anxiety within the practice of cardiology. Cardiol Rev 2009;17:36–43.
17.
Edworthy SM, Dobkin PL, Clarke AE, Da Costa D, Dritsa M, Fortin PR,Barr S, Ensworth S, Esdaile JM, Beaulieu A, Zummer M, Senécal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino A, Gladman D, Devins GM: Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol 2003;30:1011–1016.
18.
Karlson EW, Liang MH, Eaton H, Fitzgerald L, Rogers MP, Daltroy LH: A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum 2004;50:1832–1841.
19.
Braden CJ, McGlone K, Pennington F: Specific psychosocial and behavioral outcomes from the systemic lupus erythematosus self-help course. Health Educ Q 1993;20:29–41.
20.
Sohng KY: Effects of a self-management course for patients with systemic lupus erythematosus. J Adv Nurs 2003;42:479–486.
21.
Haupt M, Millen S, Jänner M, Falagan D, Fischer-Betz R, Schneider M: Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 2005;64:1618–1623.
22.
Rhee SH, Parker JC, Smarr KL, Petroski GF, Johnson JC, Hewett JE, Wright GE, Multon KD, Walker SE: Stress management in rheumatoid arthritis: what is the underlying mechanism? Arthritis Care Res 2000;13:435–442.
23.
Van Lankveld W, van Helmond T, Naring G, de Rooij DJ, van den Hoogen F: Partner participation in cognitive-behavioral self-management group treatment for patients with rheumatoid arthritis. J Rheumatol 2004;31:1738–1745.
24.
Eich W, Blumenstiel K, Lensche H, Fiehn C, Bieber C: Psychosomatics in rheumatology (in German). Z Rheumatol 2004;63:113–121.
25.
Greco CM, Rudy TH, Manzi S: Effects of a stress-reduction program on psychological function, pain and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum 2004;51:625–634.
26.
Jennekens FG, Kater L: The central nervous system in systemic lupus erythematosus. 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002;41:605–618.
27.
Seawell AH, Danoff-Burg S: Psychosocial research on systemic lupus erythematosus: a literature review. Lupus 2004;13:891–899.
28.
Segui J, Ramos-Casals M, García-Carrasco M, de Flores T, Cervera R, Valdés M, Font J, Ingelmo M: Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 2000;9:584–588.
29.
Moses N, Wiggers J, Nicholas C, Cockburn J: Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005;57:30–38.
30.
Dobkin PL, Da Costa D, Dritsa M, Fortin PR, Senecal JL, Goulet JR, Choquette D, Rich E, Beaulieu A, Cividino A, Edworthy S, Barr S, Ensworth S, Esdaile JM, Gladman D, Smith D, Zummer M, Clarke AE: Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. Arthritis Care Res 1999;12:401–410.
31.
Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, Zampieri S, Della Libera S, Perini G, Todesco S: Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004;43:1580–1586.
32.
Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983;24:385–396.
33.
Remor E: Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS). Span J Psychol 2006;9:86–93.
34.
Robles-Ortega H, Peralta-Ramírez MI: Programa para el control del estrés. Madrid, Pirámide, 2006.
35.
Beech HR, Burns LE, Sheffield BF: A Behavioral Approach to the Management of Stress: A Practical Guide to Techniques. Chichester, Wiley, 1982.
36.
Robles H, Peralta MI, Navarrete N: Validación de la versión española del inventario de vulnerabilidad al estrés de Beech, Burn y Sheffield; in Facultad de Ciencias Médicas ‘Doctor Raúl Dorticós Torrado’ (ed): Avances en Psicología de la Salud. Cienfuegos, Sider, 2006, p 62.
37.
Kohn PM, MacDonald JE: The Survey of Recent Life Experiences: a decontaminated Hassles Scale for adults. J Behav Med 1992;15:221–236.
38.
Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.
39.
Spielberger CD, Gorsuch RL, Lushene RE: STAI. Cuestionario de Ansiedad Estado-Rasgo. Madrid, TEA, 1993.
40.
Ware JE, Sherbourne CD: The MOS 36-item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
41.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–640.
42.
Sandín B, Chorot P, Santed MA, Jiménez MP: Trastornos psicosomáticos; in Belloch A (ed): Manual de psicopatología. Madrid, McGraw-Hill, 1995, pp 401–469.
43.
Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Lawrence Erlbaum, 1988.
44.
Vázquez C, Sanz J: Fiabilidad y valores normativos de la versión española del inventario para la depresión de Beck de 1978. Clin Salud 1997;8:403–422.
45.
Greco CM, Rudy TE, Manzi S: Effects of disease activity, pain and distress on activity limitations in patients with systemic lupus erythematosus. J Rheumatol 2004;31:260–267.
46.
Yen JC, Abrahamowicz M, Dobkin PL, Clarke AE, Battista RN, Fortin PR: Determinants of discordance between patients and physicians in their assessment of lupus activity. J Rheumatol 2003;30:1967–1976.
47.
Khanna S, Pal H, Pandey RM, Handa R: The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology 2004;43:1536–1540.
48.
Rinaldi S, Ghisi M, Iaccarino L, Zampieri S, Ghirardello A, Sarzi-Puttini P, Ronconi L, Perini G, Todesco S, Sanavio E, Doria A: Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:427–433.
49.
Schwartz CE, Peng CK, Lester N, Daltroy LH, Goldberger AL: Self-reported coping behavior in health and disease: assessment with a card sort game. Behav Med 1998;24:41–44.
50.
Basler HD, Kaluza G, Lledó-Boyer A: Evaluación de un programa de salud de afrontamiento al estrés. Ansiedad Estres 2003;9: 85–91.
51.
Schattner A, Naparstek Y: The future of the treatment of systemic lupus erythematosus. Clin Exp Rheumatol 2005;23:254–260.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.